- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| Fr | Cantor Fitzgerald bestätigt Einstufung für Evommune Aktie mit "Overweight" | 1 | Investing.com Deutsch | ||
| Fr | Cantor Fitzgerald reiterates Evommune stock rating at Overweight | 1 | Investing.com | ||
| Di | Evommune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | Stifel reiterates Evommune stock rating after phase 2b trial miss | 1 | Investing.com | ||
| 09.09. | RBC cuts Evommune stock price target on drug trial setback | 1 | Investing.com | ||
| 09.09. | Evommune Aktie: Analysten bestätigen Kaufempfehlung trotz Studienrückschlag | 2 | Investing.com Deutsch | ||
| 09.09. | Evommune stock maintains Buy rating despite trial setback | 1 | Investing.com | ||
| 09.09. | Evommune drops as eczema candidate fails in mid-stage trial | 1 | Seeking Alpha | ||
| 09.09. | Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail | 1 | FierceBiotech | ||
| 08.09. | Evommune's EVO756 fails phase 2b trial in atopic dermatitis | 1 | Investing.com | ||
| 07.08. | Evommune, Inc. GAAP EPS of -$0.89 | 1 | Seeking Alpha | ||
| 03.08. | Evommune Aktie: H.C. Wainwright bestätigt "Neutral"-Rating | 1 | Investing.com Deutsch | ||
| 03.08. | Evommune stock: H.C. Wainwright reiterates Neutral rating | 1 | Investing.com | ||
| 30.07. | Evommune doses first patient in migraine prevention trial | 1 | Investing.com | ||
| 30.07. | Evommune startet Phase-2b-Studie zur Migräneprophylaxe mit EVO756 | 1 | Investing.com Deutsch | ||
| 30.07. | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.06. | EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal | 1 | Zacks | ||
| 30.06. | Evommune stock downgraded by H.C. Wainwright after trial failure | 2 | Investing.com | ||
| 29.06. | Studien-Fehlschlag schickt Evommune Aktie auf Talfahrt | 7 | Investing.com Deutsch | ||
| 29.06. | Evommune's Skin Disorder Study Falls Short | 3 | Benzinga.com |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIONXT SOLUTIONS | 0,214 | -3,60 % | BioNxt Solutions: Der nächste Entwicklungssprung der Drug-Delivery-Plattform | BioNxt Solutions (0,22 EUR | 0,36 CAD | WKN: A3D1K3 | ISIN: CA0909741062 | MCAP: rund 50 Mio. CAD) entwickelt sich zunehmend von einem einzelnen Wirkstoffprojekt zu einer spezialisierten Drug-Delivery-Plattform... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,077 | +9,40 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,842 | +0,99 % | InflaRx NV-Aktie im Check am 20.09. (11:12 Uhr): Meine aktuelle Lageeinschätzung | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,370 | +0,85 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,385 | -2,78 % | Bis zu 2,1 Milliarden US-Dollar: Was die Exosomen-Deals von Eli Lilly und Takeda heute für NurExone bedeuten | ||
| IBIO | 1,109 | +1,46 % | iBio stock initiated at buy by H.C. Wainwright with $7 target | ||
| GERON | 1,159 | +2,79 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IMMUNITYBIO | 7,380 | -0,27 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,525 | +0,40 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,368 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| MANNKIND | 3,073 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,842 | -0,35 % | Ginkgo Bioworks To Build Autonomous Lab At Novo's New U.S. R&D Site In Waltham | ||
| IMMUNIC | 9,010 | -2,83 % | EQS-News: Immunic AG: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
02.09.2026 / 12:30 CET/CEST
The issuer... ► Artikel lesen |
EVOMMUNE INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,650 Euro und damit -0,05 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.